Company ProfilePremium

Realco S.A.

Company Profile Analysis

Ticker: REAL.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
Realco S.A. - Company showcase

Year Founded & Workforce

1968

50 Employees

Realco S.A. logo

Realco S.A. Employee Contacts

14 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Realco S.A. Overview

Realco is a Belgian micro-cap biotechnology and green-chemistry manufacturer. It specialises in enzyme-based hygiene, with a particular focus on detecting, removing and preventing bacterial biofilms. Founded in 1968 as a water-treatment and cleaning supplier, it was rebuilt from 1991 by the Blackman family around enzymatic formulations and moved to the Louvain-la-Neuve Science Park in 1995. Today it formulates and manufactures about 230 active products. These serve four end-markets: the food and beverage industry (about 59% of FY2025 sales), food services and retail (24%), home care through its Ecocert-certified Eezym consumer brand (12%), and health/life sciences (5%). Products are sold with audit, monitoring and training services. Realco occupies a defensible niche: proprietary enzyme–biofilm know-how, a patent estate it has enforced in court, and documented customer outcomes such as shelf-life extension. However, it is sub-scale (EUR 13.8m turnover in FY2025), thinly traded, family-controlled, and exposed to its loss-making medical spin-off OneLife. That exposure drove a EUR 0.77m net loss in FY2025.


Company's own description

In its 2024 Annual Report, Realco describes itself as a company that develops, produces and markets hygiene products derived from green chemistry. It stresses technical and scientific support "from the factory to the kitchen", aimed at high performance, safety and sustainability. Its stated mission is to co-create high-performing solutions for the ecological transition. It defines four sectors of activity (2024 Annual Report, "Secteurs d'activités"):

Food industry: Farming, meat, dairy, micro-breweries and other processors, where Realco positions itself as an expert in bacterial decontamination that preserves freshness "from farm to fork".

Health: The Biosafety expertise pole serves pharmaceutical and cosmetics manufacturers (Life Sciences), while the biomedical spin-off OneLife addresses decontamination of medical devices and hospital environments.

Food services and retail: Restaurants, collective catering, butchers and food retail.

Home: The Eezym range of household products made with renewable, naturally derived ingredients ("#homedetox").

Business model and revenue model

Realco is a formulator-manufacturer. It buys enzymes (obtained by microbial fermentation from bacteria, yeasts or fungi), surfactants, Ecocert-compliant raw materials and packaging. It formulates and fills products at its rebuilt Louvain-la-Neuve plant and sells them:

  1. Directly to industrial food processors, collective catering and healthcare/life-science sites, typically bundled with audit, protocol design, training (Realco Academy), monitoring and technical support. The 2024 report notes that spending on technical equipment and services for customer support roughly tripled versus 2019.

  2. Through distributors and retail chains, for example specialised DIY and food-retail chains for Eezym, and distributors such as the REPA group catalogue for professional products. The 2024 report lists DIY and food retail chains among its customer channels.

  3. Through subsidiaries. Realzyme LLC (US, 75%-owned, commercial only) buys from Realco and resells in North America. OneLife SA (33.85%) buys enzymatic products manufactured by Realco for the medical market.

Revenue-mix characterisation (analyst estimate, not company-disclosed): product sales are the overwhelming majority of revenue. Services (audits, biofilm treatment interventions, filtration performance programmes, training) are embedded in pricing or billed alongside products. There is no subscription or licensing revenue of note. The company also resells non-enzymatic disinfectants it does not manufacture (2024 Annual Report). It manufactured certain chemical products for Fluidra for four years after the 2021 pool-business sale (press release, 25 March 2021).

Value-chain position

Realco sits between industrial enzyme producers (upstream: global biotech suppliers) and end users. Its value-add is formulation IP (multi-enzyme synergies with green-chemistry surfactants), application know-how (biofilm sampling, detection and removal protocols; membrane-filtration audits), and regulatory dossiers (REACH/CLP, biocide registrations, Ecocert). It is not an enzyme producer. That makes it a price-taker on its key input, while its service intensity differentiates it from commodity detergent suppliers.

Customer types and end-markets

End-marketSub-segments named by companyRepresentative customer outcome (company-reported)
Food industryDairy, meat and fish, soft drinks, beer, bakery and confectionery, ready meals, plant-basedA meat-sector customer reported fresh-burger shelf life (DLC) extended from 11 to 23 days; a dairy customer improved membrane-filtration water flux (website testimonials)
Food services and retailRestaurants, collective kitchens, retail, supermarketsA central hospital kitchen replaced caustic soda-based products and reported reduced skin problems for staff (website)
HealthLife Sciences (pharma, cosmetics); medical devices via OneLifeBiofilm detection on surgical instruments (blue stain) plus enzymatic removal (OneLife)
HomeEezym consumer rangeConsumer testimonials (website)

Independent characterisation

Realco is best understood as a niche specialty-chemicals SME with a biotech narrative. Its economics resemble a small industrial-hygiene supplier: labour cost is about 33% of revenue, product-level gross margins are in the mid-to-high 60s percent, and EBIT margins are in the low-to-mid single digits. It carries an option on higher-value applications in biofilm control, shelf-life extension and medical decontamination. Divesting the pool and spa brands in 2021 removed about EUR 5m of commodity-chemistry revenue, but it also removed about half of the 2019 carbon footprint. Since then, B2B food industry has become the growth engine, rising from about 56% to 59% of sales between FY2023 and FY2025.

Strategy

Stated strategy themes (paraphrased from company documents)

  1. Refocus on enzymatic green chemistry and high value-added B2B. The pool and spa sale was explicitly framed as ending exposure to "classic chemistry" and concentrating on environmentally friendly, high value-added products and services (CEO, press release, March 2021). Since then, strong B2B growth has raised the share of high value-added sales (2024 Annual Report).

  2. Biofilm leadership and international growth. The pool sale was intended to accelerate international expansion in the "fight against biofilms" and to fund Eezym (March 2021).

  3. External growth. In October 2021 Realco mandated E-Spring Capital to acquire a B2B industrial food-hygiene company in a neighbouring country. A board member described an acquisition as an essential growth engine amid sector consolidation. No acquisition has been announced in the five years since.

  4. Innovation pipeline. Nine projects were cited in 2021. The 2024 Annual Report describes two axes: disruptive new products, and incremental re-engineering. Named projects are Cold Cleaning, SuCoLib, SampleZym, CleanPack (terminated) and KillZym.

  5. "People, Planet, Prosperity" sustainability framework. The company targets "healthy and virtuous organic growth" and maps its strategy to the UN SDGs (2, 3, 6, 8, 9, 13, 14, 15).

  6. Organisational transformation. Holacracy-inspired shared governance is being rolled out step by step from 2024, with a "vision committee" and training investments.

Initiatives announced or advanced in the last 24 months (Oct 2024 – Oct 2026)

InitiativeTypeDetailStatusSource
KillZym / KillZymeR&D, new productNatural-ingredient biocide for the food industry to reduce the ecological footprint of disinfection and contribute to antimicrobial-resistance mitigation; partners ULiège (CIP), UCLouvain (LDRI), B12 Consulting (bio-informatics); funded via the Wagralim competitiveness clusterApplications filed Mar and Sep 2024; kick-off at Realco on 2 April (2025, per lab start date); lab work from 20252024 Annual Report; LinkedIn
SuCoLibR&DNatural compounds plus enzymes against Listeria monocytogenes biofilms in the salmon industry; Walloon recoverable advances (30% fixed repayment 2026–2030; 70% variable at 3.53% of product turnover)Research phase ended late 2025NBB FY2025 note 15; 2024 Annual Report
SampleZymR&DEnzymatic sampling method to detect microorganisms missed by classic swabbing; poster at the French Society of Microbiology national congressIn development2024 Annual Report
Cold Cleaning extensionProductLow-temperature enzymatic formulas extended to new food, catering and retail rangesOngoing2024 Annual Report
Eco-formulation definition and LCAsESG, productObjective definition of "eco-formulation" to score the whole portfolio; first product LCA (flagship food-industry product) with more planned2024 onwards2024 Annual Report
ERP modernisationOperationsTo streamline processes and support capacity growthIn progress2024 Annual Report
Undenatured alcohol licenceRegulatory, ESGBecome an approved holder of undenatured alcohol (target 2025) to eliminate suspected endocrine-disrupting denaturantsTarget 2025; outcome not disclosed2024 Annual Report
Mobility policy and Akt for Wallonia mobility auditESG, costFormal business-travel policy from 20252,0252024 Annual Report
EcoVadisESGFirst submission in May 2026, silver medalCompletedCompany news (Jun 2026)
OneLife financingPortfolioBridge convertible loan in Dec 2024; FY2025 write-down of EUR 1.25mOngoing exposure2024 Annual Report; NBB FY2025

Cost programmes

No formal cost-reduction programme with quantified targets has been disclosed. Margin protection measures include a tariff-revision process introduced to pass through raw-material, energy and automatic wage-indexation inflation (2024 Annual Report).

Medium-term financial targets and guidance

Not publicly disclosed. Realco issues no revenue, margin or EPS guidance.

The only quantified "growth" target identified concerns the associate OneLife: in 2021 it aimed for EUR 20m annual revenue by 2026 (La Libre). With FY2024 turnover of EUR 0.89m and a FY2025 loss of EUR 1.2m, this target will clearly not be met.

Non-financial 2030 targets include:

  • Scope 1+2 emissions −46% and Scope 3 −18% versus 2019;

  • 25% of sales from Ecocert products;

  • 50% recycled plastic in primary packaging;

  • zero aquatic-toxic detergents;

  • water intensity below 1 m³ per tonne produced.

Products & Services

Realco discloses about 230 active formulas (2024 Annual Report). Individual product SKU names, prices and launch years are largely not published. The catalogue below is organised by sector and expertise pole, using company-published descriptions. Pricing models are not publicly disclosed for any line.

Food industry

OfferingDescription and capabilitiesTarget customerLaunch / latest versionSource
Biofilm Expert Services (Biosafety pole)Patented methodology to audit installations, then detect, eliminate and prevent biofilm contamination; combines enzymatic cleaning, which breaks the biofilm matrix so disinfection can reach the bacteria, with sampling and monitoringMeat, dairy, beverage, ready-meal and plant-based processorsMethodology validated by research published Sep 2020; ongoingWebsite; 2024 Annual Report; DH (2020)
Shelf-life extension programmesEnzymatic cleaning protocols shown in the Biofilm Expert study to extend use-by dates by up to 100% (one customer example: 11 to 23 days on fresh burgers)Fresh-food processors2020 onwardsPress page; website
Membrane filtration range and Performance Optimization ProgramProducts tailored to unit type and fouling, plus audit, treatment and monitoring, to raise filter throughput, cut cleaning, water and energy costs and extend membrane lifeDairy (whey, milk protein), beverageOngoing; filtration formulas being reformulated to exit aquatic-toxicity Category 3 by 2030Website; 2024 Annual Report
Cold-cleaning enzymatic formulasEnzyme formulations effective at low temperature; energy savings for users; being extended to new rangesFood industry, catering, retailCommercialised since 2023; extended in 20242024 Annual Report
"Global & sustainable hygiene" range (Conscious / Essential Cleaning)Full product range plus support to adopt hygiene solutions aligned with each sector's sustainability goals; "the right dose for controlled hygiene"All B2B sectorsOngoing2024 Annual Report; website
Water treatment packagesEnzymatic products that accelerate biodegradation of organic loads in wastewater; maintenance of water-treatment systems; tailored packages per installationFood plants, kitchens, healthcare sitesHistoric core activity since 1968Website; 2024 Annual Report
Resold non-enzymatic disinfectantsComplementary disinfectants Realco does not manufacture but supplies; denaturant control to be strengthened in 2026B2B customersOngoing2024 Annual Report

Food services and retail

OfferingDescriptionTarget customerSource
Enzymatic surface and floor cleaner-disinfectantsLiquid enzymatic products for floors, walls, worktops and epoxy; dosed at 0.5–1% in warm water (35–50°C) via Venturi dispensers; about 15 minutes contact time; claimed to prevent pipe clogging through continued enzyme actionCollective kitchens, schools, hospitals, butchersRealco product sheets (2014)
Dishwashing productsMachine dishwashing range (about 4% of sales volume in 2024)Restaurants, collective catering2024 Annual Report
Co-branding programmesDevelopment of Food Services through co-branding and long-term partnerships to raise the share of Ecocert-certified salesDistributors, catering groups2024 Annual Report
Realco Academy, audit and technical supportTraining, on-site follow-up, didactic materials, PPE guidanceAll professional usersWebsite; 2024 Annual Report

Health

OfferingDescriptionTarget customerSource
Life Sciences Biosafety rangeHygiene and biofilm control products and services for pharmaceutical and cosmetics production; higher water-quality standards requiredPharma and cosmetics plants2024 Annual Report (range launched 2023)
OneLife medical range (via 33.85%-owned OneLife SA)Biofilm detection (blue colouring of biofilm on instruments) plus enzymatic detergents that dissolve biofilm and bioburden on medical devices and hospital surfaces; ISO 13485-certified; also endoscope inspection equipment (borescopes) sold in BelgiumHospitals, central sterile services, dental and animal careDH (2013); Dealroom; 2024 Annual Report

Home

OfferingDescriptionTarget customerSource—
Eezym (#homedetox)Enzyme-based household cleaners from naturally derived renewable ingredients, Ecocert Greenlife "Ecodétergent" certified; multi-purpose cleaner and dish spray cited by customers; bottles 100% PCR since the 2024 relaunch; about EUR 1.0m sales in 2024Consumers via retail and DIY chains and webshopLaunched 2017; relaunched 2024L'Avenir (2017); 2024 Annual Report

Discontinued or divested

OfferingStatusSource
Splash (pool maintenance) and Zen (spa)Sold to Manufacturas Gre SAU (Fluidra) on 14 Oct 2021; market leaders in Belgian retail pool and spa care; about EUR 5m turnover in 2020Press releases (Mar and Oct 2021)
CleanPack (pea-starch biopolymer doses)Project terminated after partner PolyPea's bankruptcy (Oct 2024)2024 Annual Report

Portfolio health metrics (2024 Annual Report)

  • No formula is classified CMR (carcinogenic, mutagenic or reprotoxic); the company has committed to exclude known and suspected endocrine disruptors.

  • 91% of the detergent range is free of aquatic-toxicity classification; the target is zero toxic-classified detergents by 2030.

  • 40 Ecocert-certified references in 2024 (5 in 2019), representing 19% of sales volume; the target is 25% by 2030.

  • About 20% of the portfolio consists of acid or alkaline solutions reserved for professional uses (filtration, dishwashing, descaling).

  • Two inhalation-classified formulas, used in closed circuits only, represent about 4% of sales volume.

  • 15 new formulas were being launched in 2024 (+7% portfolio), and 30 of 230 formulas (13%) were re-engineered.

Product Portfolio

OfferingDescriptionTarget customerSource

Eezym (#homedetox)

Enzyme-based household cleaners from naturally derived renewable ingredients, Ecocert Greenlife "Ecodétergent" certified; multi-purpose cleaner and dish spray cited by customers; bottles 100% PCR since the 2024 relaunch; about EUR 1.0m sales in 2024

Consumers via retail and DIY chains and webshop

Launched 2017; relaunched 2024

L'Avenir (2017); 2024 Annual Report

Financial Detail

Revenue by Segment

SegmentFY2023FY2024FY2025

Food industry revenue (EUR K)

6,5666,7118,105

Food services and retail revenue (EUR K)

3,2293,7653,280

Home revenue (EUR K)

1,6031,4891,671

Health revenue (EUR K)

285449736

Total turnover (EUR K)

11,68412,41513,792

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment growth and mix (%)

Segment growth and mix (%)FY2023FY2024FY2025

Food industry YoY growth (%)

—2.220.8

Food services YoY growth (%)

23.316.6-12.9

Home YoY growth (%)

—-7.112.2

Health YoY growth (%)

—57.663.8

Food industry share of turnover (%)

56.254.158.8

Food services share of turnover (%)

27.630.323.8

Home share of turnover (%)

13.712.012.1

Health share of turnover (%)

2.43.65.3

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Turnover (EUR K)

13,6219,72311,68412,41513,792

Total operating income incl. other income and capitalised development (EUR K)

———13,43414,714

Purchases and goods for resale (EUR K)

—3,5174,2334,1814,360

Product gross profit = turnover − purchases (EUR K, analyst-calculated)

—6,2067,4518,2349,433

Gross margin, NBB definition (EUR K)

—3,7794,9965,4206,545

Services and other goods (EUR K)

———3,6173,791

Personnel costs (EUR K)

3,4613,8004,2194,3364,562

Depreciation and amortisation (EUR K)

———9941,166

Operating result / EBIT (EUR K)

—189207265781

EBITDA (EUR K)

3,3755578921,2871,947

Financial income (EUR K)

———108224

Financial charges incl. non-recurring (EUR K)

———2381,795

Pre-tax result (EUR K)

———136-790

Income taxes (EUR K)

———66

Net result (EUR K)

2,036124259157-771

EPS basic, approximate (EUR, on about 643,610 shares)

3.160.190.400.24-1.20

Dividend declared, total (EUR K)

———3000

Dividend per share, approximate (EUR)

———0.470.00

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Turnover growth YoY (%)

—-28.620.26.311.1

Product gross margin (%)

—63.863.866.368.4

Gross margin, NBB definition (% of turnover)

—38.942.843.747.5

EBITDA margin (%)

24.85.77.610.414.1

Operating (EBIT) margin (%)

—1.91.82.15.7

Net margin (%)

14.951.282.221.26-5.59

Personnel costs / turnover (%)

25.4139.0836.1134.9333.08

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (EUR K)

13,35617,39017,32116,83115,685

Intangible assets (EUR K)

———404697

Tangible assets (EUR K)

———8,2487,582

Financial fixed assets (EUR K)

———2,8101,539

Inventories (EUR K)

———1,7191,569

Trade receivables (EUR K)

———2,5072,482

Other receivables (EUR K)

———775444

Cash and equivalents (EUR K)

2,7831,1917093091,322

Long-term financial debt (EUR K)

———4,2013,903

Short-term financial debt, current portion of LT debt (EUR K)

———778718

Total financial debt (EUR K)

———4,9794,621

Net financial debt (EUR K)

———4,6693,299

Total liabilities excl. equity and provisions (EUR K)

5,2228,0837,9916,9846,790

Provisions (EUR K)

———518454

Shareholders' equity (EUR K)

7,1828,4398,6999,2818,441

Goodwill (EUR K)

00000

Working capital = current assets − current liabilities (EUR K)

———2,5853,005

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Capex: tangible + intangible + capitalised development, derived from fixed-asset notes (EUR K)

————792

Dividends paid in year (EUR K)

————300

Share buybacks (EUR K)

00000

Net change in cash (EUR K)

—-1,592-482-3991,013

Net financial debt repayment (EUR K)

————357

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE on year-end equity (%)

28.371.472.981.69-9.13

ROA on year-end assets (%)

—0.711.500.93-4.91

Pre-tax ROIC proxy = EBIT / (equity + net debt) (%)

———1.96.7

Current ratio (x)

———1.932.05

Financial debt / equity (x)

———0.540.55

Net debt / EBITDA (x)

———3.711.69

Interest coverage = EBIT / recurring financial charges (x)

———1.122.82

Asset turnover = turnover / year-end assets (x)

—0.560.670.740.88

Days sales outstanding (days)

———7466

Days inventory outstanding on purchases (days)

———150131

Days payables outstanding on purchases + services (days)

———5752

Cash conversion cycle (days)

———167145

Region / Country Details

Region / countryEvidenceSource

Belgium (home market)

Primary market; most sales occur in Belgium per aggregator descriptions; close to 50% of procurement spend is also Belgian

FMP profile; 2024 Annual Report

France

French establishment (SIREN 507 486 637) registered since 2008; cited among export markets

Pappers; FMP

Italy

Linked partner site Piramide Ambiente ("our expertise in Italy"); Italian-language detergent catalogues distributed via REPA. One third-party profile refers to "subsidiaries in the US and Italy", but no Italian participation of ≥10% appears in the NBB FY2025 participation list

Website; MTEC profile; NBB

Spain, Germany, Eastern Europe

Cited export markets; multilingual REPA catalogues; participation in an industry event in Bucharest (ESE 2026, 11–12 March 2026)

FMP; LinkedIn

Japan

Cited export market; one customer invoiced in yen

FMP; 2024 Annual Report (FX risk section)

United States

Realzyme LLC (Springboro, Ohio), 75%-owned: FY2023 revenue USD 1.398m (+12.8%), net ordinary income USD 127k; FY2025 net income USD 179k, equity USD 382k. About 74% of Realzyme sales are Biofilm and Filtration ranges

2024 Annual Report; NBB FY2025

Revenue by Region

MetricFY2024

OneLife sales in Belgium (EUR K)

311

OneLife sales via European distributors (EUR K)

269

OneLife export sales (EUR K)

306

OneLife total turnover (EUR K)

888

OneLife turnover (EUR K, read from 2024 Annual Report chart)

OneLife turnover (EUR K, read from 2024 Annual Report chart)FY2020FY2021FY2022FY2023FY2024

OneLife turnover (EUR K)

701762507733888

Margin Analysis (%) (FY2019–FY2025)

MetricFY2019FY2020FY2021FY2022FY2023FY2024FY2025

Calendar-year share price change (%)

25.00-11.20-13.969.95-11.90-16.2221.29

Valuation Multiples

MultipleRealco

Market capitalisation

About EUR 11.3m

Enterprise value (market cap + net financial debt EUR 3.3m)

About EUR 14.6m

P/E (FY2025)

Not meaningful (EPS −1.20)

P/E (FY2024 EPS 0.24)

About 73x

EV/EBITDA (FY2025 EBITDA EUR 1.95m)

About 7.5x (about 9.4x excluding EUR 402k capitalised development)

EV/Sales (FY2025)

About 1.06x

P/B (FY2025 equity EUR 8.44m)

About 1.34x

Dividends & Capital Returns

MetricFY2024FY2025

Total dividend declared (EUR K)

3000

Debt Maturity Profile

Maturity bucketAmount (EUR K)

Due within 1 year

718

Due in 1–5 years (credit institutions 2,664; lease 95)

2,759

Due after 5 years

1,144

Total financial debt

4,621

Analyst Conclusions

Management guidance and consensus

Management guidance: not publicly disclosed. Qualitative direction from the 2024 Annual Report and the 2021 press releases: continue B2B organic growth, invest in innovation and sustainability, seek external growth, and strengthen shared governance.

Consensus: none.

Bull case

  1. Operating inflection is real. On a comparable perimeter, turnover compounded at about 12% over FY2022–FY2025. Product gross margin expanded about 460 bp to 68.4% after re-internalisation. Even excluding capitalised development, EBIT roughly doubled in FY2025. Continued food-industry growth (+20.8%) on a largely fixed cost base could take EBIT margins towards high single digits.

  2. The OneLife overhang is largely provisioned. After the EUR 1.25m write-down, residual exposure is EUR 1.53m of book value. Realco also benefits commercially from OneLife as a customer: Health sales rose to EUR 736k. Any OneLife partnering or exit would be upside against a cleaned-up base.

  3. The valuation is undemanding for a niche IP owner. At about 1.06x EV/Sales, about 7.5x EV/EBITDA and 1.34x P/B, the market pays little for the patent estate, the profitable US subsidiary (independently valued at USD 1.5m for 100% equity in 2023) or the pipeline. Deleveraging (net debt/EBITDA from 3.7x to 1.7x) restores capacity for bolt-on M&A or a resumed dividend.

Bear case

  1. Underlying profitability remains thin and flattered. Before FY2025, EBIT never exceeded 2.1% of sales. FY2025 EBIT includes EUR 268k from a change in accounting policy, and the Food services decline (−12.9%) is unexplained.

  2. Capital allocation and governance concerns. Cumulative investment in OneLife (EUR 1.65m to 2024, plus further conversions) has largely been written off against an unrealistic EUR 20m revenue target. The EUR 300k FY2024 dividend exceeded net income just before a loss year. The board is family-concentrated with no disclosed committees.

  3. Structural scale and liquidity discount. At EUR 13.8m turnover, Realco competes against multinationals with service networks. Disclosure is minimal (no cash-flow statement, no shareholder percentages). Trading on Euronext Access is sporadic. The five-year share performance is about −15%, which limits re-rating potential.

Key catalysts and monitorables (next 12 months)

H1/FY2026 trading: whether Food industry growth persists and Food services stabilises. Look for the FY2026 results announcement around May 2027.

OneLife: further funding rounds, dilution, partnering, or additional write-downs.

Pipeline: SuCoLib commercialisation (royalty-style repayment signals revenue), KillZym regulatory pathway, SampleZym.

M&A: any announcement under the long-standing acquisition strategy.

Dividend policy: whether distributions resume once retained earnings (EUR −596k at end-2025) turn positive.

Governance: content of the June–July 2026 board changes; any formal committee structure.

ESG: progress on SBTi Scope 1+2, Ecocert share and recycled packaging; leverage of EcoVadis silver in corporate tenders.

Balance sheet: cash conversion, scheduled debt amortisation (EUR 718k in 2026) and SuCoLib repayments.

Analyst verdict

Realco is a credible but sub-scale specialist that has spent six years repairing itself. The 2020 fire forced three and a half years of subcontracting. The 2021 sale of the Splash and Zen pool brands removed a third of revenue and half of the carbon footprint. The company then rebuilt a modern, insured plant financed by indemnities, bank debt and Walloon subsidies. The FY2025 statutory accounts show that this repair is working at the operating level: record turnover of EUR 13.8m, product gross margin of 68%, EBIT of EUR 0.78m, and net debt down to EUR 3.3m (1.7x EBITDA). The technology is genuine: patented enzyme–biofilm formulations, a court-enforced IP position, and documented shelf-life benefits. It is also well aligned with food processors' safety, waste and decarbonisation agendas.

The investment case, however, is constrained by three factors that the market rightly discounts. First, the core remains marginally profitable once one strips out the newly capitalised development costs: underlying EBIT is about 3.7% of sales. Second, capital allocation has been uneven. Most of the money put into OneLife has been written off, the promised acquisition never materialised, and a dividend larger than profit was paid just before a loss. Third, governance and disclosure fall short of institutional standards. There is family control of the Chair, CEO and CFO roles, no published committees, no cash-flow statement, no shareholder register percentages and no analyst coverage. Liquidity on Euronext Access is minimal.

At about EUR 11m market cap (about 1.1x EV/Sales, about 1.3x book), the shares price in little growth. Upside depends on sustained double-digit food-industry growth, stabilisation of food services, no further OneLife drain, and visible commercialisation of the SuCoLib and KillZym pipeline. Investors with a long horizon and tolerance for illiquidity may find asymmetric value. For most institutional mandates, Realco remains a watch-list name until two consecutive years of clean, cash-backed profitability and improved governance disclosure are delivered.


DATA QUALITY & DISCREPANCY NOTES

  1. FY2024 net result: EUR 156.7k (statutory, NBB / Companyweb) versus EUR 263.9k (2024 Annual Report). The difference is a EUR 107.2k withdrawal from untaxed reserves.

  2. FY2025 revenue: EUR 13.79m turnover (NBB) versus EUR 14.71m "revenue" (Stockanalysis, equal to total operating income) versus EUR 14.19m trailing-twelve-month (Yahoo).

  3. FY2024 total assets: EUR 16,830.8k (NBB) versus EUR 16,829.1k (2024 Annual Report); immaterial.

  4. Share count: about 643,610 (Simply Wall St) versus 635,700 (FMP, April 2024).

  5. EBITDA definitions: Signumi (FY2022–FY2024) versus analyst EBIT + D&A (FY2025); third-party EBITDA of EUR 0.53m (MarketInOut) uses a different basis.

  6. FY2021 figures: derived from Boursorama ratios and Signumi year-on-year changes; approximate.

  7. FY2023 segment revenue: derived from FY2024 growth rates in the 2024 Annual Report; reconciles to the reported total.

  8. Erroneous aggregator profiles: Twelve Data (real estate description) and Tracxn (bacteriophage company, 113 employees) misidentify the company and were disregarded.

  9. Signed FY2025 management report: published as an image-only PDF and not machine-readable. FY2025 management commentary (drivers of the Food services decline, outlook) therefore could not be extracted.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

DirectorRepresented byRoleMandateBackground (public information)Source

Oxygen SA

Gordon Blackman

Chairman

28 May 2024 – AGM 2026

Acquired Realco in 1991; former CEO; reference shareholder through Oxygen SA

NBB FY2025; investor page

D2G SRL

George Blackman

Managing director (administrateur délégué) and CEO

30 May 2023 – AGM 2026

CEO since 2017 (own statement, 2021 press release); on the board since about 2013 (Investing.com)

NBB; press release

Dare Consulting SRL

Frédéric Tiberghien

Director

25 May 2024 – AGM 2026

On the board since 2021; spokesperson on M&A strategy in 2021

NBB; press release (Oct 2021)

Sparaxis SA

Jean-Luc Nondonfaz

Director

28 May 2024 – AGM 2026

Represents Sparaxis SA (Liège-based investment company)

NBB

Nomainvest SA

Bernard Jolly

Director

27 May 2025 – AGM 2027

Represents shareholder Nomainvest SA

NBB; investor page

Xavier Sinéchal

—

Director

28 May 2024 – AGM 2026

Director since about 2013

NBB; Investing.com

Victoria Blackman

—

Director (also CFO since 2025)

27 May 2025 – AGM 2027

Family member; joined as CFO in 2025

NBB; 2024 Annual Report

Nathalie Guillaume

—

Director

27 May 2025 – AGM 2027

Joined in 2024; affiliated with Danone (per company announcement)

NBB; company news (Jul 2024)

Aline Le Clef

—

Director

27 May 2025 – AGM 2027

Joined in 2024; affiliated with Sodexo (per company announcement)

NBB; company news (Jul 2024)

Executive Leadership Team

NameFunctionNotes

George Blackman

CEO

Also managing director via D2G SRL

Victoria Blackman

CFO

Joined in 2025

Sandrine Antoniou

People Partner

Leads the shift to holacracy-inspired shared governance

Thibault Wauters

Food & Beverage North

Sales lead, northern region

Laurent Paul

Food & Beverage South

Sales lead, southern region

Tania Florent

Food Services

—

Luk Van den Berghe

B2C (Eezym)

—

Valentine Neirynck

Marketing & Communication

Also press contact

Sébastien Fastrez

Research & Development

Named partner in the KillZyme project

Philippe Demyttenaere

Operations

—

Board & Management Changes

DateChangeContext

3 Jul 2024

Aline Le Clef and Nathalie Guillaume join the board

Board evaluation in 2023 led to recruitment of profiles from customer-adjacent sectors (catering, food)

2025

Victoria Blackman appointed CFO

Strengthens female representation in governance (2024 Annual Report)

27 May 2025

AGM: appointments and renewals to 2027 (V. Blackman, N. Guillaume, A. Le Clef, Nomainvest/B. Jolly); Deloitte appointed auditor to 2028

NBB FY2025

26 May 2026

AGM: several mandates expired (Oxygen, D2G, Dare Consulting, Sparaxis, X. Sinéchal)

Investor page; Companyweb

Dec 2021

Koen Billet becomes CEO of OneLife (associate)

La Libre

Major Shareholders

HolderNature

Oxygen SA

Holding vehicle of Gordon Blackman (Chairman)

Nomainvest SA (Eupen)

Investor; board seat

WE Environnement S.A.

Analyst inference: likely the environmental investment vehicle of Wallonie Entreprendre, successor of SRIW, Realco's long-standing public shareholder that supported the company after the 2020 fire (unconfirmed)

Founding shareholders

Family and founders

Free float (Euronext Access)

Public

Competitive Landscape

Competitors by Segment

SegmentCompetitorPositioning versus Realco

Food industry hygiene (CIP, open-plant cleaning, membrane cleaning)

Ecolab (US)

Global leader in food and beverage hygiene with service-intensive model; scale, global accounts, enzymatic membrane cleaners within a broad portfolio

Food industry hygiene

Diversey (now part of Solenis, US)

Major food and beverage and institutional hygiene supplier

Food industry hygiene

Kersia (France)

Food-safety and biosecurity specialist from farm to fork; direct overlap in biofilm and food-processing hygiene

Food industry hygiene

Christeyns (Belgium)

Belgian family-owned hygiene group; food hygiene and professional laundry; local competitor

Enzymes / biosolutions

Novonesis (Denmark)

Leading enzyme producer; potential supplier and competitor in biological cleaning and wastewater biosolutions

Food services / institutional

Ecolab, Diversey/Solenis, Christeyns, Orapi (France)

Broad institutional chemical ranges; Realco differentiates on enzymatic, pH-neutral, worker-safe formulations

Medical device decontamination (OneLife)

Steris (US/Ireland); Ruhof (US); Dr. Weigert (Germany)

Established enzymatic instrument-detergent suppliers with hospital channel scale

Home eco-cleaning (Eezym)

Ecover / Method (SC Johnson); Frosch (Werner & Mertz); L'Arbre Vert (France)

Mass-market eco brands with retail scale; Eezym differentiates on enzymes and Ecocert certification but is sub-scale (about EUR 1.0m in 2024)

Wastewater bio-treatment

Novonesis and specialty biological-product suppliers

Overlap in grease and organic-load degradation products

Competitor Detail

MetricRealco FY2025

Revenue

EUR 13.8m

Revenue growth

+11.1%

EBIT margin

5.7% (about 3.7% excluding capitalised development)

Product gross margin

68.4% (turnover − purchases)

R&D intensity

Not disclosed (third-party claim >15%)

Recent Developments

Realco is a micro-cap on Euronext Access with sparse disclosure. All identified items are listed below, including smaller ones.

Company Snapshot

$15.5M

Revenue

50

Employees

1968

Founded

Louvain-la-Neuve, Belgium

Headquarters

SWOT Analysis

Strengths

  • Margin recovery after re-internalisation. NBB-definition gross margin rose from 38.9% (FY2022) to 47.5% (FY2025); product gross margin from 63.8% to 68.4% (NBB / Companyweb).
  • Comparable-perimeter growth. Turnover grew at about 12.4% CAGR over FY2022–FY2025 to a record EUR 13.8m (NBB).
  • Validated differentiated outcomes. The Biofilm Expert study with ULiège and Genalyse showed shelf-life extension of up to 100%; one customer went from 11 to 23 days DLC (press page; website).
  • Enforced IP. Realco won its January 2021 counterfeiting case; patents EP1025052 and EP1987125B1 underpin the range (press release; product sheets).
  • Modern, insured, de-risked asset base. The rebuilt plant (2023) has ESFR sprinklers, PV panels and rainwater harvesting, and secured a EUR 470k Walloon investment premium (2024 Annual Report).
  • ESG credentials valued by corporate buyers. These include ISO 14001 (2024), EcoVadis silver (2026), zero CMR formulas, 91% non-aquatic-toxic detergents, and an SBTi commitment (2024 Annual Report; company news).

Weaknesses

  • Sub-scale. EUR 13.8m turnover and 50.3 FTE in FY2025 (NBB) limit purchasing power and international reach.
  • Thin underlying profitability. EBIT margin was 1.8–2.1% in FY2022–FY2024. The FY2025 5.7% includes EUR 268k from newly capitalised development (NBB note 6.19).
  • Heavy working capital. The cash conversion cycle was about 145–167 days (FY2024–FY2025, analyst-calculated), and cash fell as low as EUR 309k at end-2024 (NBB).
  • Limited disclosure. There is no consolidated accounts, cash-flow statement, geographic split, R&D spend, shareholder percentages or segment profit (NBB FY2025).
  • Family-concentrated governance. Three of nine board seats and the CEO, CFO and Chair roles are held by the Blackman family, with no disclosed committees (NBB; investor page).
  • Volatile Food services line. It fell 12.9% in FY2025 after two years of double-digit growth, with no published explanation (NBB note 6.10).

Opportunities

  • Food industry momentum. +20.8% growth in FY2025, to EUR 8.1m (NBB).
  • Health and Life Sciences. Sales rose from EUR 285k (FY2023, derived) to EUR 736k (FY2025), as the new plant enables production for OneLife and the Life Sciences range (2024 Annual Report).
  • Pipeline commercialisation. SuCoLib's research ended in 2025, with product royalty-style repayment of 3.53% of turnover. KillZym is in the lab from 2025 (NBB; 2024 Annual Report).
  • US scale-up through Realzyme. Realzyme is profitable (FY2025 net income USD 179k), and 74% of its sales are high-value biofilm and filtration lines (NBB; 2024 Annual Report).
  • Bolt-on M&A in neighbouring markets. The E-Spring mandate shows intent, and the balance sheet has improved (net debt/EBITDA 1.7x in FY2025).
  • Customer decarbonisation. Cold cleaning and filtration efficiency can be quantified through LCAs, which Realco started in 2024 (2024 Annual Report).

Threats

  • OneLife. Negative equity of EUR −823k and a FY2025 loss of EUR −1.2m (NBB) may require more support or further write-downs; the remaining book value of participations is EUR 1.53m.
  • Customer concentration. Two important partners decreased sharply in 2024 (2024 Annual Report).
  • Input-cost and wage inflation. Automatic indexation was flagged as a key risk (2024 Annual Report).
  • Regulatory reclassification. The ethanol denaturant was listed as a suspected endocrine disruptor, forcing reformulation; biocide regulation affects KillZym (2024 Annual Report).
  • Larger competitors. Ecolab, Solenis–Diversey and Kersia can bundle enzymatic offers with global service networks.
  • Liquidity and valuation discount. The stock trades on Euronext Access with no analyst coverage (Simply Wall St). It has fallen in four of the last seven calendar years (Zonebourse).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
3 Apr 2025Publication of the 2024 customer satisfaction (NPS) survey results Company newsCustomer-centric KPI tracking
2 Apr 2025 (year inferred)KillZyme consortium kick-off at Realco with ULiège, UCLouvain and B12 Consulting LinkedIn; 2024 Annual ReportStart of the natural-biocide R&D programme
14 May 2025FY2024 results published: turnover EUR 12.41m (+6.3%), EBIT EUR 265k (+28%), net result EUR 157k Zonebourse; 2024 Annual ReportConfirmed margin recovery after re-internalising production
15 May 202530th anniversary of Realco's presence at the Louvain-la-Neuve Science Park LLN Science ParkCorporate milestone
27 May 2025AGM: approval of FY2024 accounts including a EUR 300k dividend; appointment of Deloitte (to 2028); director appointments to 2027 NBB FY2025Governance refresh; capital return
2025Victoria Blackman appointed CFO 2024 Annual ReportFinance leadership change within the family
22 Jul 2025Moniteur belge publication: resignations and appointments CompanywebFormalises AGM board changes
26 Aug 2025FY2024 annual accounts filed with the National Bank of Belgium CompanywebStatutory compliance
Sep–Oct 2025Third sustainability / annual report ("People Planet Prosperity 2024") published 2024 Annual ReportDetailed ESG metrics, segment data, subsidiary data
Late 2025SuCoLib research phase completed; fixed repayment of Walloon advances scheduled for 2026–2030 NBB FY2025Future cash outflow; potential product commercialisation
FY2025 (year-end)EUR 1.25m write-down of the OneLife participation; EUR 119k financial provision NBB FY2025Main driver of the FY2025 net loss
FY2025 (year-end)Change in valuation rules: first capitalisation of development costs (EUR 402k; +EUR 268k pre-tax effect) NBB FY2025Flatters FY2025 EBIT; affects comparability
FY2025Realzyme FY2025 net income USD 179k NBB FY2025Profitable US subsidiary
25 Feb 2026Share price about USD 21.19 (about EUR 18–20), market cap about USD 13.6m (PitchBook snapshot)Valuation reference
9 Mar 2026Market cap EUR 10.62m; trailing EPS −1.20; debt/equity 0.55 (MarketInOut)Valuation reference after FY2025 numbers
11–12 Mar 2026Participation in the ESE 2026 event in Bucharest (international business development, biofilm detection) LinkedInEastern Europe market development
13 May 2026FY2025 results published: record turnover EUR 13.79m (+11.1%); EBIT EUR 781k; net loss EUR −771k Zonebourse; NBB FY2025Earnings inflection at operating level; loss from OneLife
18 May 2026Investor page updated with AGM convocation, proxy, FY2025 management report and accountsDisclosure
May 2026First EcoVadis assessment: silver medal Company news (9 Jun 2026)ESG credential for corporate food and catering customers
26 May 2026Ordinary AGM: approval of FY2025 accounts; no dividend (loss carried forward); several director mandates up for renewal Investor page; NBB FY2025Capital return paused
2 Jun 2026FY2025 accounts filed with the NBB CompanywebStatutory compliance
24 Jun 2026Moniteur belge publication: resignations and appointments CompanywebBoard changes after the AGM
29 Jul 2026Moniteur belge publication: resignations and appointments CompanywebFurther governance changes
3 Sep 2026Share price EUR 17.70 StockanalysisValuation reference
Early Oct 2026Share price EUR 17.60; market cap EUR 11.3m; 52-week range EUR 11.40–27.00 Yahoo FinanceCurrent valuation

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Turnover rose from EUR 13.6 Mn in FY2021 to EUR 13.8 Mn in FY2025.
Realco S.A. — Income Statement: Revenue & Gross Profit
Series (EUR Mn)FY2021FY2022FY2023FY2024FY2025
Turnover13.69.711.712.413.8
Product gross profit = turnover − purchases—6.27.58.29.4
Gross margin, NBB definition—3.855.46.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Realco SA — FY2025 annual accounts, NBB format, approved by the AGM of 26 May 2026 (realco.be)
  2. Realco SA — 2024 Annual / Sustainability Report "People Planet Prosperity" (published Sept–Oct 2025) (realco.be)
  3. Realco — Investor page (AGM 2026, accounts FY2017–FY2025, shareholders, board) (realco.be)
  4. Realco — Website home page (sectors, expertise poles, SDG commitments, news) (realco.be)
  5. Realco — Press releases (fire 2020, Biofilm Expert, counterfeiting judgment 2021, Fluidra sale Mar and Oct 2021) (realco.be)
  6. FSMA — Trading suspension (10 Jan 2020) (fsma.be)
  7. FSMA — Trading resumption (15 Jan 2020) (fsma.be)
  8. Mondo Visione / Euronext — New listing on Euronext: Realco S.A. (14 Jun 2006) (mondovisione.com)
  9. Companyweb — Realco SA financial data and publications (companyweb.be)
  10. Signumi — Realco historical financials (signumi.com)
  11. Boursorama — Realco key figures (boursorama.com)
  12. Zonebourse — Results announcements and share-price history: and: zonebourse.com · zonebourse.com
  13. Rendementbourse — Realco finances (rendementbourse.com)
  14. Yahoo Finance — REAL.BR quote (finance.yahoo.com)
  15. Investing.com — Realco quote and company profile: and: uk.investing.com · investing.com
  16. Stockanalysis — Realco company profile and revenue: and: stockanalysis.com · stockanalysis.com
  17. Simply Wall St — Realco company information (simplywall.st)
  18. Financial Modeling Prep — Realco profile (site.financialmodelingprep.com)
  19. MarketInOut — Realco fundamentals (marketinout.com)
  20. PitchBook — Realco profile (pitchbook.com)
  21. LLN Science Park — "Realco: 30 years at LLN Science Park" (2025) (llnsciencepark.be)
  22. L'Avenir — "Realco continues to develop its biotech products" (27 Apr 2017) (lavenir.net)
  23. TVCom — "The success story of Realco and its enzymes" (tvcom.be)
  24. La Libre — OneLife capital increase and 2026 target (17 Dec 2021) (lalibre.be)
  25. DH — OneLife launch (27 Nov 2013) (dhnet.be)
  26. DH — Shelf-life extension research (23 Sep 2020) (dhnet.be)
  27. Belgian Prime Minister archive — Visit to Realco (15 Sep 2015) (archive.premier.be)
  28. Medical-Xprt — Realco company profile (medical-xprt.com)
  29. Dealroom / One.gob.es — OneLife SA profile (startups.one.gob.es)
  30. OneLife — Investor page (onelife-prod.odoo.com)
  31. LinkedIn — KillZyme kick-off and ESE 2026 posts (Christophe Nilsson) (be.linkedin.com)
  32. Realco product sheets and REPA catalogues (patent references, dosage): and: gev-online.com · gev-online.com
  33. MTEC — Realco profile (mtec-sc.org)
  34. Pappers / Societe.com — Realco French establishment (SIREN 507 486 637) (pappers.fr)
  35. Trends Top (Knack) — Realco profile (trendstop.knack.be)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.